Successful olaparib desensitization using a novel one-day protocol

Allergy, Asthma & Clinical Immunology

Hannah Roberts¹  Rongbo Zhu¹  Stephen Welch² 

[1] Division of Clinical Immunology and Allergy, Department of Medicine, Western University;Division of Medical Oncology, Department of Oncology, Western University;

关键词: Olaparib;    Drug desensitization;    Drug allergy;    Chemotherapy agent;   

DOI  :  10.1186/s13223-020-00499-x

来源: DOAJ

【 摘 要 】

Abstract Background Olaparib is a revolutionary treatment for patients with ovarian and breast cancer. Currently, there is no established 1-day drug desensitization protocol for patients with olaparib type-1 hypersensitivity reactions despite well documented IgE-mediated adverse reactions occurring with olaparib. Case presentation We report a 58-year-old female with immediate, reproducible IgE-mediated adverse reactions to olaparib tablets with implementation of a 1-day novel desensitization protocol to olaparib. Following desensitization, the patient was successfully transitioned from olaparib capsules to tablets with no loss of tolerance. Conclusions To our knowledge, this is the first reported case of successful olaparib desensitization using a novel 1-day desensitization protocol, and will contribute to drug allergy knowledge, in an area where robust data is lacking. This case demonstrates the important role for drug desensitization in patients with immediate hypersensitivity reactions to chemotherapeutic agents. Furthermore, as olaparib capsules are being phased out in favour of olaparib tablets, we provide a clear case that transitioning from capsule to tablet form did not cause a loss of tolerance.

【 授权许可】

Unknown